Statement by Michael A. Carrier to Senate Judiciary Committee on 'Intellectual Property and the Price of Prescription Drugs: Balancing Innovation and Competition'
Senate Judiciary Committee hearing May 7, 2019
2 Pages Posted: 6 Sep 2019
Date Written: May 7, 2019
In my testimony to the Senate Judiciary Committee, I explained the benefits of legislation addressing anticompetitive conduct that brand-name drug companies have employed: sample denials, pay-for-delay settlements, citizen petitions, product hopping, and patent thickets. By increasing generic competition, this legislation would make patients’ lives better without affecting innovation.
Keywords: pharmaceuticals, drugs, antitrust, sample denials, pay-for-delay settlements, citizen petitions, product hopping, patent thickets
JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38
Suggested Citation: Suggested Citation